Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.

Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). PLoS One (2015) 1.39

Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Clin Rheumatol (2016) 0.77

Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol Int (2016) 0.76

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment. Intern Med (2017) 0.75

Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature (2009) 9.71

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis (2007) 4.05

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (2004) 3.92

PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol (2002) 3.37

An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell (2007) 3.34

Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood (2008) 2.53

Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol (2006) 2.44

Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol (2009) 2.42

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol (2008) 2.42

Defective vasculogenesis in systemic sclerosis. Lancet (2004) 2.38

RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum (2009) 2.37

Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum (2006) 2.19

Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol (2011) 2.15

Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum (2005) 2.11

Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis. Arthritis Rheumatol (2015) 2.02

Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol (2015) 1.99

Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med (2005) 1.93

Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat Immunol (2002) 1.92

Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol (2003) 1.76

Serum indicators for the diagnosis of pneumocystis pneumonia. Chest (2007) 1.73

Keys to success for a school-based malaria control program in primary schools in Thailand. Parasitol Int (2006) 1.71

Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig (2013) 1.70

School-based participatory health education for malaria control in Ghana: engaging children as health messengers. Malar J (2010) 1.68

Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) (2009) 1.58

Remarkable genetic polymorphism among Entamoeba histolytica isolates from a limited geographic area. J Clin Microbiol (2002) 1.53

Geographic diversity among genotypes of Entamoeba histolytica field isolates. J Clin Microbiol (2003) 1.49

A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol (2006) 1.46

Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) (2009) 1.43

ADAMTS5 is a biomarker for prediction of response to infliximab in patients with rheumatoid arthritis. J Rheumatol (2010) 1.42

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol (2009) 1.39

Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J Immunol (2003) 1.37

Identification and characterization of two isoenzymes of methionine gamma-lyase from Entamoeba histolytica: a key enzyme of sulfur-amino acid degradation in an anaerobic parasitic protist that lacks forward and reverse trans-sulfuration pathways. J Biol Chem (2003) 1.34

Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost (2009) 1.33

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol (2008) 1.29

Proposed [corrected] Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol (2005) 1.28

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis (2011) 1.27

A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol (2002) 1.26

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol (2007) 1.25

Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken) (2013) 1.25

Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) (2010) 1.25

Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea (2003) 1.25

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol (2007) 1.21

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. Rheumatology (Oxford) (2011) 1.21

Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) (2012) 1.21

The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) (2012) 1.20

Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis. Mod Rheumatol (2011) 1.20

Human circulating monocytes as multipotential progenitors. Keio J Med (2007) 1.20

Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol (2005) 1.17

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis (2011) 1.16

Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol (2005) 1.15

Interaction of KLRG1 with E-cadherin: new functional and structural insights. Eur J Immunol (2008) 1.13

Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One (2013) 1.13

Clinically amyopathic dermatomyositis. Curr Opin Rheumatol (2010) 1.13

Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun (2005) 1.13

Abnormal protein profiles in tears with dry eye syndrome. Am J Ophthalmol (2003) 1.12

Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol (2012) 1.11

Guidelines for the proper use of etanercept in Japan. Mod Rheumatol (2006) 1.10

IL-7 exacerbates chronic colitis with expansion of memory IL-7Rhigh CD4+ mucosal T cells in mice. Am J Physiol Gastrointest Liver Physiol (2004) 1.10

Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA (2009) 1.10

Diversity of clinical isolates of Entamoeba histolytica in Japan. Arch Med Res (2006) 1.09

Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum (2009) 1.09

Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) (2011) 1.09

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol (2007) 1.09

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol (2010) 1.08

Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med (2008) 1.08

Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) (2012) 1.08

The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol (2010) 1.07

Identification of an avirulent Entamoeba histolytica strain with unique tRNA-linked short tandem repeat markers. Parasitol Int (2009) 1.06

Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol (2012) 1.06

Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol (2011) 1.06

Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. Invest Ophthalmol Vis Sci (2003) 1.05

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol (2011) 1.05

Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med (2010) 1.05

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol (2011) 1.05

Derivation of multipotent progenitors from human circulating CD14+ monocytes. Exp Hematol (2010) 1.05

Cardiomyogenic potential of mesenchymal progenitors derived from human circulating CD14+ monocytes. Stem Cells Dev (2005) 1.05

In vivo role of IFN-gamma produced by antigen-presenting cells in early host defense against intracellular pathogens. Eur J Immunol (2003) 1.05

Visual cycle protein RPE65 persists in new retinal cells during retinal regeneration of adult newt. J Comp Neurol (2006) 1.05

Exome sequencing identifies novel rheumatoid arthritis-susceptible variants in the BTNL2. J Hum Genet (2013) 1.04

Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis (2012) 1.04

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol (2011) 1.04

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol (2013) 1.03

Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol (2008) 1.02

Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome. Arthritis Res Ther (2011) 1.01

Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol (2014) 1.01

Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells. Biochem Biophys Res Commun (2009) 1.01